Generic Medicine Info
Indications and Dosage
Dysmenorrhoea, Gastrointestinal tract spasm
Adult: 60-120 mg 1-3 times daily.
Child: ≥12 yr Same as adult dose.
Paralytic ileus, intestinal obstruction. Pregnancy and lactation.
Special Precautions
Patient w/ severe constipation, fever, abnormal vag bleeding/discharge, dysuria, blood from the bowel. Childn.
Adverse Reactions
Nausea, headache, dizziness; allergic reaction, anaphylaxis, dyspnoea, wheezing; pruritus, rash, jaundice, hepatitis.
Patient Counseling Information
This drug may cause dizziness, if affected, do not drive or operate machinery.
Symptoms: Hypotension, atropine-like effects. Management: Supportive treatment. Manage atropine-like effects as for atropine poisoning.
Description: Alverine, an antispasmodic agent, acts directly on intestinal and uterine smooth muscle. It non-specifically reduces contractions induced by acetylcholine, histamine, and 5-hydroxytryptamine (5-HT).
Absorption: Absorbed from the GI tract. Time to peak plasma concentration: 1-1.5 hr.
Metabolism: Rapidly metabolised to an active primary metabolite, then further metabolised to 2 secondary metabolites.
Excretion: Via urine.
Chemical Structure

Chemical Structure Image

Source: National Center for Biotechnology Information. PubChem Database. Alverine, CID=3678, (accessed on Jan. 20, 2020)

Store below 25°C. Protect from light.
MIMS Class
ATC Classification
A03AX08 - alverine ; Belongs to the class of other drugs used for functional bowel disorders.
Anon. Alverine. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. Accessed 02/09/2016.

Buckingham R (ed). Alverine Citrate. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. Accessed 02/09/2016.

Joint Formulary Committee. Alverine Citrate. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. Accessed 02/09/2016.

Disclaimer: This information is independently developed by MIMS based on Alverine from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 MIMS. All rights reserved. Powered by
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $139 a year.
Sign up for free
Already a member? Sign in